Gilead Oncology Trodelvy Dosing and Administration | GileadPro

For GB healthcare professionals only. This page contains promotional content
Adverse Event Reporting Prescribing Information

The recommended dose of Trodelvy® is 10 mg/kg administered as an intravenous infusion once weekly on Days 1 and 8 of 21-day treatment cycles1


Watch this short video to learn more about how to appropriately dose and administer Trodelvy®.
(Video duration: 03:49 minutes)

  1. Trodelvy® GB Summary of Product Characteristics. Gilead Sciences Ltd. Available at: https://www.medicines.org.uk/emc/product/12880. Accessed January 2024.

March 2024 UK-TRO-0919

Adverse events should be reported

For the UK, reporting forms and information can be found at www.mhra.gov.uk/yellowcard or via the Yellow Card app (download from the Apple App Store or Google Play Store). Adverse events should also be reported to Gilead to [email protected] or +44 (0) 1223 897500.